Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is a clinical-stage biotechnology company pioneering targeted therapies for cancers with high unmet medical needs. This page serves as the definitive source for verified news and official updates, providing stakeholders with timely insights into the company's progress in oncology drug development.
Investors and researchers will find curated press releases covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on Salarius' protein degradation therapies and inhibitor candidates, financial disclosures, and collaborative research initiatives in precision medicine.
All content is rigorously sourced from SEC filings, corporate communications, and validated industry reports. The repository is maintained to support informed analysis while adhering to financial compliance standards. Bookmark this page for efficient tracking of SLRX's advancements in addressing gene dysregulation through innovative biopharmaceutical approaches.
Salarius Pharmaceuticals (SLRX) reports significant advancements in its drug development programs, notably with SP-3164 and seclidemstat. The FDA pre-IND meeting for SP-3164 has been successfully completed, setting the stage for further studies. Financially, Salarius had $24.2 million in cash as of March 31, 2022, but reported a net loss of $6.1 million for Q1 2022, up from $1.9 million in Q1 2021, primarily due to increased R&D expenses. The annual stockholders meeting is scheduled for June 15, 2022, inviting participation in key proposals.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced plans to submit an Investigational New Drug (IND) application for SP-3164 in 2023 after successfully completing a pre-IND meeting with the FDA. SP-3164 is a next-generation targeted protein degrader aimed at treating hematological and solid tumors. This novel agent may effectively eliminate cancer-causing proteins. The FDA provided critical feedback aiding in the preparation for the IND submission and subsequent clinical trials. Salarius aims to leverage SP-3164 amidst its ongoing clinical programs in an evolving cancer treatment landscape.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a conference call scheduled for May 12, 2022, at 5:00 p.m. ET to discuss its financial results for the first quarter of 2022. Interested participants can join via phone or listen to the live webcast on the company's investor relations website. Salarius is focused on developing innovative cancer therapies, including seclidemstat, which is in clinical trials for conditions such as Ewing sarcoma. The product has received multiple designations from the FDA, emphasizing its potential in treating unmet medical needs.
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has announced a registered direct offering, securing approximately $2.3 million through the sale of 9,339,436 shares at $0.25 per share. The offering, facilitated by Ladenburg Thalmann & Co. Inc., is set to close around April 26, 2022 and aims to fund clinical and pre-clinical development and general corporate purposes. Additionally, unregistered warrants for 7,004,578 shares with an exercise price of $0.3399 will also be issued to investors.
On March 10, 2022, Salarius Pharmaceuticals (SLRX) reported key corporate events and financial results for 2021. The company expanded its cancer therapy pipeline by acquiring SP-3164, a targeted protein degrader aimed at treating hematologic and solid tumors. Salarius reported a net loss of $12.8 million for the year, with cash reserves totaling $29.2 million, expected to support operations through 2023. Upcoming updates on clinical trials for both SP-3164 and seclidemstat are anticipated, with optimism for growth in 2022 and beyond.
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and audio webcast on March 10, 2022, at 5:00 p.m. ET to discuss its financial results for the year ended December 31, 2021. The call will provide insights into its clinical developments, including seclidemstat, a cancer therapy in Phase 1/2 trials for Ewing sarcoma. The company has secured Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA for this indication. Interested participants can join via provided U.S. and international phone numbers.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on February 24, 2022, at 10:20 a.m. ET. The presentation will focus on the company’s progress, including the Phase 1/2 clinical trial of seclidemstat, aimed at treating sarcomas and pediatric cancers, and recent acquisitions in protein degradation assets like SP-3164. Investors can register for free to attend the conference, with a recording available post-event on the company’s website.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the BIO CEO & Investor Conference, February 14-17, 2022, in New York. The presentation will cover Salarius' recent achievements, including the acquisition of targeted protein degradation assets for new drug development and updates on the seclidemstat clinical program. Attendees will have access to on-demand content and can schedule one-on-one meetings with the management team. Salarius focuses on developing therapies for sarcomas and pediatric cancers, with its lead candidate seclidemstat currently in clinical trials.
Salarius Pharmaceuticals announces the appointment of Dr. Daniela Santiesteban as Director of their new targeted protein degradation program, focusing on SP-3164. This role follows Salarius' expansion into targeted protein degradation through the acquisition of SP-3164 from DeuteRx. Dr. Santiesteban will oversee SP-3164's clinical trials, expected to file an IND with the FDA in the first half of 2023. SP-3164 aims to treat various cancers, building on the efficacy of previous compounds like avadomide while enhancing safety.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a transformative acquisition of a targeted protein degradation portfolio from DeuteRx, significantly enhancing its oncology pipeline. The acquisition includes the lead candidate SP-3164 (formerly DRX-164), which is set to enter clinical trials in 2023. Salarius aims to develop this candidate and additional assets targeting previously undruggable cancer-promoting proteins. The agreement involves an upfront payment of $1.5 million and shares, with potential future payments totaling up to $188 million based on milestones.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
